Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 748Observational 5Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Cisplatin × Clear all
NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Eli Lilly and Company

Approved for marketing
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡